MLTX News and Press, MoonLake Immunotherapeutics

2024-06-23 06:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-05-09 08:19:46 ET Summary I present additional information about my methodology for finding the best stocks. Some of the technical tools I use to make final decisions to buy or sell. The leadership of certain stocks and sectors changes occasionally, and we can take this i...

2023-05-04 03:08:32 ET Summary My journey on the road to finding the best portfolio. My early attempts to find the best stocks in which to invest. My success in finding the best methods. I feel it is about time to publish my latest stock recommendations as I have, I ...

ZUG, Switzerland, May 3, 2023 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has signed a collaboration agreement with SHL Medical,...

2023-04-27 09:30:23 ET Summary MoonLake is a small Swiss company which licensed a great asset from Merck KGaA. This molecule, sonelokimab, produced potentially better data than blockbuster cosentyx. They are a bit low on cash. MoonLake Immunotherapeutics (MLTX), base...

ZUG, Switzerland, April 19, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host today its Capital Markets Day for investors and analysts in New...

2023-03-20 10:29:09 ET Gainers: Lifecore Biomedical ( LFCR ) +41% . Connect Biopharma ( CNTB ) +27% . InMed Pharmaceuticals ( INM ) +21% . ReShape Lifesciences ( RSLS ) +21% . Bellerophon Therapeutics ( BLPH ) +15% . Losers...

2023-03-20 09:03:14 ET MoonLake Immunotherapeutics press release ( NASDAQ: MLTX ): Q4 GAAP EPS of -$0.31. Cash cash and equivalents of $72.1M Research and development expenses for the fourth quarter ended December 31, 2022 were $11.4 million, compared to $9.0 mill...

MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update Strong financial position: year-end cash, cash equivalents and short-term marketable debt securities of $ 72.1 million, expected to provide runway well i...

Cantor Fitzgerald launched its coverage on MoonLake Immunotherapeutics ( NASDAQ: MLTX ) with an Overweight recommendation on Tuesday, citing $1.5B potential for Sonelokimab, the company's experimental therapy for skin disease Hidradenitis Suppurativa (HS). The analyst Prakhar Agrawal ...